Search research articles
Contact Us
Filters
Showing results (221-230 of 259) with videos related to
Page
of 26
Sort By:
Annals of the Rheumatic Diseases
|
May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
JHEP Reports : Innovation in Hepatology
|
January 2, 2026
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice
Emmanuel Somm, Elodie Perroud, Yunju Jo, et al.
Blood
|
January 13, 2018
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Eric S Weiss, Charlotte Girard-Guyonvarc'h, Dirk Holzinger, et al.
Annals of the Rheumatic Diseases
|
October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases
|
February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Cem Gabay, Bruno Fautrel, Jürgen Rech, et al.
Annals of the Rheumatic Diseases
|
May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
Kim Lauper, Dan C Nordström, Karel Pavelka, et al.
Seminars in Arthritis and Rheumatism
|
July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis
Kim Lauper, Denis Mongin, Florenzo Iannone, et al.
European Journal of Immunology
|
March 8, 2018
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection
Katy A Lloyd, Johanna Steen, Khaled Amara, et al.
Hepatology Communications
|
November 23, 2025
Interleukin-18 binding protein protects against metabolic steatohepatitis
Emmanuel Somm, Yunju Jo, Elodie Perroud, et al.
Annals of the Rheumatic Diseases
|
September 17, 2015
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Cem Gabay, Myriam Riek, Merete Lund Hetland, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 259) with videos related to
Sort By:
Page
of 26
Annals of the Rheumatic Diseases
|
May 17, 2011
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
JHEP Reports : Innovation in Hepatology
|
January 2, 2026
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice
Emmanuel Somm, Elodie Perroud, Yunju Jo, et al.
Blood
|
January 13, 2018
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Eric S Weiss, Charlotte Girard-Guyonvarc'h, Dirk Holzinger, et al.
Annals of the Rheumatic Diseases
|
October 6, 2011
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, et al.
Annals of the Rheumatic Diseases
|
February 24, 2018
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Cem Gabay, Bruno Fautrel, Jürgen Rech, et al.
Annals of the Rheumatic Diseases
|
May 7, 2018
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
Kim Lauper, Dan C Nordström, Karel Pavelka, et al.
Seminars in Arthritis and Rheumatism
|
July 9, 2019
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis
Kim Lauper, Denis Mongin, Florenzo Iannone, et al.
European Journal of Immunology
|
March 8, 2018
Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B-cell selection
Katy A Lloyd, Johanna Steen, Khaled Amara, et al.
Hepatology Communications
|
November 23, 2025
Interleukin-18 binding protein protects against metabolic steatohepatitis
Emmanuel Somm, Yunju Jo, Elodie Perroud, et al.
Annals of the Rheumatic Diseases
|
September 17, 2015
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Cem Gabay, Myriam Riek, Merete Lund Hetland, et al.
Page
of 26